Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3093 |
|
Actual shortage: | 246 (8%) | |
Anticipated shortage: | 15 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2823 (91%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
31 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-FROVATRIPTAN | 2.5MG | TABLET | Resolved | 2023-07-13 | 2023-07-21 | 198508 |
APO-FUROSEMIDE | 20MG | TABLET | Resolved | 2024-03-22 | 2024-04-19 | 223067 |
APO-GABAPENTIN | 800MG | TABLET | Resolved | 2017-09-26 | 2017-10-31 | 23558 |
APO-GABAPENTIN | 600MG | TABLET | Resolved | 2017-11-28 | 2018-03-22 | 31001 |
APO-GABAPENTIN | 800MG | TABLET | Resolved | 2017-11-28 | 2018-03-22 | 31004 |
APO-GABAPENTIN | 600MG | TABLET | Resolved | 2019-01-09 | 2019-01-12 | 71662 |
APO-GABAPENTIN | 600MG | TABLET | Resolved | 2019-03-13 | 2019-07-04 | 78505 |
APO-GABAPENTIN | 800MG | TABLET | Resolved | 2019-03-27 | 2019-05-21 | 79580 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-01-22 | 2021-01-27 | 132355 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-03-26 | 2021-05-01 | 136400 |
APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2021-07-05 | 2021-07-08 | 141851 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-07-09 | 2021-08-16 | 142275 |
APO-GABAPENTIN | 100MG | CAPSULE | Resolved | 2021-07-23 | 2021-10-28 | 142976 |
APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2021-09-17 | 2021-11-22 | 145837 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2021-10-08 | 2021-10-29 | 146904 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2022-01-07 | 2022-01-31 | 152310 |
APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2017-03-11 | 2017-03-29 | 604 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2017-03-11 | 2017-07-13 | 661 |
APO-GABAPENTIN | 400MG | CAPSULE | Resolved | 2017-04-07 | 2017-09-15 | 5897 |
APO-GABAPENTIN | 300MG | CAPSULE | Resolved | 2017-06-06 | 2017-08-16 | 12064 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |